Why Moderna Stock Just Crashed 21%
's (NASDAQ: MRNA) sales are slowing down, and Moderna stock is going down -- a lot.
The coronavirus vaccine maker's shares plunged 21.2% through 10:20 a.m. ET Monday after it updated investors on its 2024 performance and released new guidance for 2025.
Moderna estimates it ended 2024 with somewhere between $3 billion and $3.1 billion in product sales as it shifted its business toward treating COVID-19 as an "endemic" illness rather than a novel and spreading pandemic. CEO Stéphane Bancel said Moderna has cut its "cash operating cost by over 25 percent compared to 2023" and plans to make further cost cuts of $1 billion in 2025 and $500 million more in 2026, which should boost profits.
Source Fool.com
Moderna Inc. Stock
€25.75
1.200%
Based on 9 Buy predictions and 10 Sell predictions the sentiment towards Moderna Inc. is rather balanced.
With a target price of 22 € there is a slightly negative potential of -14.55% for Moderna Inc. compared to the current price of 25.75 €.
